NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem Profile by BTV
Business Television (BTV) visited NeoStem to speak with Dr. Robin Smith, Chairman and CEO, and Dr. Douglas Losordo,Chief Medical Officer,
News + EventsNeoStem Announces Licensing of Patent Portfolio from the Rockefeller University Expanding its Cancer Immunotherapy Intellectual Property Portfolio September 11, 2014 - Learn MoreNeoStem and PCT, A NeoStem Company, to Present at Multiple September Conferences September 9, 2014 - Learn MoreNeoStem Letter to Shareholders September 8, 2014 - Learn More
Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to p.... Read More